Instituto de Química y Fisicoquímica Biológicas (IQUIFIB), Laboratorio de Oncología y Transducción de Señales, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Junín 956, C1113AAD, Buenos Aires, Argentina.
Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Instituto de Química Rosario (CONICET-UNR), Suipacha 531, 2000, Rosario, Argentina.
J Cancer Res Clin Oncol. 2022 Dec;148(12):3361-3373. doi: 10.1007/s00432-022-04129-4. Epub 2022 Jun 25.
To investigate the effect of TAP7f, a penicillin derivative previously characterized as a potent antitumor agent that promotes ER stress and apoptosis, in combination with thapsigargin, an ER stress inducer, on melanoma cells.
The synergistic antiproliferative effect of TAP7f in combination with thapsigargin was studied in vitro in murine B16-F0 melanoma cells, and in human A375 and SB2 melanoma cells. In vivo assays were performed with C57BL/6J mice challenged with B16-F0 cells. Immunofluorescence and Western blot assays were carried out to characterize the induction of ER stress and apoptosis. Necrotic tumor areas and the potential toxicity of the combined therapy were examined by histological analysis of tissue sections after hematoxylin-eosin staining.
In vitro, the combination of TAP7f with thapsigargin synergistically inhibited the proliferation of murine B16-F0, and human A375 and SB2 melanoma cells. When non-inhibitory doses of each drug were simultaneously administered to C57BL/6J mice challenged with B16-F0 cells, a 50% reduction in tumor volumes was obtained in the combined group. An apoptotic response characterized by higher expression levels of Baxenhanced PARP-1 cleavage and the presence of active caspase 3 was observed in tumors from the combined treatment. In addition, higher expression levels of GADD153/CHOP and ATF4 were found in tumors of mice treated with both drugs with respect to each drug used alone, indicating the induction of an ER stress response. No signs of tissue toxicity were observed in histological sections of different organs extracted from mice receiving the combination.
The synergistic and effective antitumor action of TAP7f in combination with thapsigargin could be considered as a potential therapeutic strategy for melanoma treatment.
研究 TAP7f(一种先前被表征为促进内质网应激和细胞凋亡的强效抗肿瘤剂的青霉素衍生物)与内质网应激诱导剂他普西卡丁联合应用于黑色素瘤细胞的效果。
在体外,于小鼠 B16-F0 黑色素瘤细胞、人 A375 和 SB2 黑色素瘤细胞中研究 TAP7f 与他普西卡丁联合的协同抗增殖作用。在 C57BL/6J 小鼠中进行体内实验,用 B16-F0 细胞对其进行挑战。通过免疫荧光和 Western blot 实验来分析内质网应激和细胞凋亡的诱导。通过苏木精-伊红染色的组织切片进行组织学分析,检测坏死性肿瘤区域和联合治疗的潜在毒性。
体外实验表明,TAP7f 与他普西卡丁联合可协同抑制小鼠 B16-F0 和人 A375 和 SB2 黑色素瘤细胞的增殖。当非抑制剂量的每种药物同时给予 C57BL/6J 小鼠,用 B16-F0 细胞进行挑战时,联合组的肿瘤体积减少了 50%。在联合治疗的肿瘤中观察到一种凋亡反应,其特征是 Bax 表达水平升高、PARP-1 切割增强和活性 caspase 3 的存在。此外,与每种药物单独使用相比,在两种药物联合治疗的小鼠肿瘤中发现 GADD153/CHOP 和 ATF4 的表达水平更高,表明内质网应激反应的诱导。在接受联合治疗的小鼠不同器官的组织切片中未观察到组织毒性的迹象。
TAP7f 与他普西卡丁联合应用具有协同且有效的抗肿瘤作用,可被视为治疗黑色素瘤的潜在治疗策略。